Article

Tyrosine kinase inhibitors target B cells

2023-02-23

Abstract excerpt

Autoimmune disorders and some types of blood cancer originate when B lymphocytes malfunction. In particular, when B cells produce antibodies recognizing the body’s proteins, it leads to various autoimmune disorders. And when B cells of various developmental stages transform into cancer cells, it results in blood cancers, including multiple myeloma, lymphoma, and leukemia. Thus, new methods of targeting B cells are...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e853a822-118d-5cb8-89e5-49a444ecc574
DOI: 10.1101/2023.02.23.529681

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

Tyrosine kinase inhibitors target B cellsDOI 10.1101/2023.02.23.529681Read

Tyrosine Kinase ALK/LTK Inhibitors Target B LymphocytesSemantic proximity Read

CD4⁺ T-cell reserve predicts bispecific antibody efficacy and can be enhanced by BTK inhibition in B-cell lymphomaSemantic proximity Read

Targeting BMI-1 to deplete antibody-secreting cells in autoimmunitySemantic proximity Read

Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?Semantic proximity Read

Investigation of novel therapeutic strategies in B cell and antibody mediated diseaseSemantic proximity Read

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future DirectionsSemantic proximity Read

Targeting plasma cells: are we any closer to a panacea for diseases of antibody-secreting cells?Semantic proximity Read

Characterization of Human B Cell Hematological Malignancies Using Protein-Based ApproachesSemantic proximity Read